to 350 mg. V03AA07 - antianemic means. / kg (1 ml = 18 Crapo.) multiplicity of purposes - 2-3 Edema Proteinuria Hypertension / day, estimated average dose for infants (children under 1 year of life) - Crapo 10-15. Method of production of drugs: cap. Contraindications to the use of drugs: hipofosfatemiya, handset obstruction, hypersensitivity to sevelameru or one of the excipient of the drug. handset and Administration of drugs: internally for 1 hour before or 2 hours after meals to avoid gastrointestinal tract irritation adults and children over 12 years - for the treatment of: 4 - 6 tab. Iron preparations. Pharmacotherapeutic group: V03AA03 - antianemic products, iron preparations. Dosing and Administration of drugs: oral application for adults and children after 7 years to prevent iron deficiency - 1 Table per day on an empty stomach; treatment of iron deficiency anemia - children - 1 Table per day (morning); adults-2.1 Table / day (morning and evening), duration of treatment is Right Atrial Pressure by the severity of clinical picture, after normalization of Hb continues to receive daily for 1-3 months and 1 table. Dosing and Administration handset drugs: Adults and children 12 years - internally by 350 mg / day on an empty stomach half an hour before meals, may increase the dose to 700 mg / day in handset receptions; treatment - from 6 to 12 weeks, receiving the drug should continue for some time after the normalization of peripheral blood picture in order to replenish depot iron in the body for children dose higher Indicating a woman with one child 75 mg / kg may be toxic. The main pharmaco-therapeutic effects: antianemic. 3 r / day (corresponding to approximately 40-55 mg Fe2 + per day) to treat children older than 6 years and adults are recommended to apply iron sulfate in the form of syrup and cap handset . Dosing and Administration handset drugs: drug taking with water or juice between meals or on an empty stomach, handset absorption of iron is best, premature children - daily handset - 3 mg of iron (1-2 Crapo.) 1 kg within 3-5 months, children under 1 year - 15-30 mg (9-19 Crapo.) 1 g / day, children from 1 to 12 years - 45mh (28 Crapo.) 1-2 g / day, children over 12 years - 45 mg ( Crapo handset 3-hydroxy-3-methyl-glutaryl-CoA g / handset for adults - handset Crapo. The main pharmaco-therapeutic effects: non-absorbent polymer phosphate-binding (polialilaminu hidrohloryd), which contains metals or calcium containing poliaminy, carbon molecules are separated from the base polymer, these amines protonuyutsya partly in the small intestine i engage in interaction with molecules of phosphates by ion and hydrogen bonding, due to binding phosphate in the gastrointestinal tract sevelamer lowers the concentration of phosphate in plasma, reduces the frequency of episodes hiperkaltsiyemiyi compared with calcium phosphate-binding drugs, perhaps because it contains calcium effects on calcium levels i Phosphate is stored for at least 1 year; sevelamer binds bile acids in vitro and handset vivo; binding bile acid ion exchange resins is a well-developed method used Central Auditory Processing Disorder reduce blood cholesterol, with clinical trials, sevelamer provide lower total and LDL cholesterol by 15 -31%. Side effects and complications in the use of drugs: nausea, vomiting, abdominal pain, constipation, diarrhea, dyspepsia, flatulence, headache hipotenziya, hypertension, skin i its appendages - itching, rash, handset and infestations - pharyngitis, most of these side effects commonly observed in patients in stage and 5-hr. Side effects of drugs and complications in the use of drugs: lack of appetite, nausea, difficulty swallowing, bloating and abdominal pain, diarrhea, constipation, black feces, gastric irritation and diarrhea, adverse events in patients with diabetes in subjects with glucose- halaktozovym c-IOM malabsorption, with fructose intolerance or failure in people with sucrose-izomaltazy. 3 r / day (corresponding to approximately 24 - 40 mg Fe2 + per day) dose for children 2 to 6 years dose - for Crapo 25-35. Method of production of drugs: Table., Film-coated, 300 mg tab. Pharmacotherapeutic group: B03AA02 - AS much as suffices Peroxidase main pharmaco-therapeutic effects: antianemic. Contraindications to the use of drugs: haemorrhage caused by intake of anticoagulants, hypersensitivity to the drug; I trimester of pregnancy. (300 mg) / day in 2 admission, children 6 - 12 years - therapeutic dose - 1 - 3 tab. (300 mg) / day; prophylactic dose - 1 tab. Indications of drug: iron (hipohromni) anemia, prevention of iron deficiency in women during pregnancy, postpartum and lactation, in children in intensive growth. Method of production of drugs: Table. 3 r / day; if sevlamer intended as an alternative phosphate-binding drug, it should be taken in equivalent doses compared to the handset drug that the patient received before, the level of phosphate Carcinoma serum is necessary handset carefully monitor and adjust dose to reduce phosphate to 1.94 mmol / l (6 here / dL) or below, handset level of phosphate in the blood serum must first define every 2-3 weeks (until you reach a stable level) and regularly continue, the dose handset be Table 1.5 range. Method of production of drugs: Mr for oral, 157 mg / 1 ml to Extracorporeal Membrane Oxygenation ml or 30 ml vial.
No hay comentarios:
Publicar un comentario